Skip to main content

Advertisement

Table 1 Comparison of growth kinetics (doubling time) of RT112, RT112rGEMCI20, RT112luc, and RT112rGEMCI20luc cell lines and cell viability (IC50) after treatment with gemcitabine

From: Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

Cell line Doubling time (h) IC50 (ng/ml)
RT112 23.28 ± 2.88 1.63 ± 0.55
RT112rGEMCI20 25.2 ± 3.12 125.40 ± 29.78
RT112luc 24.72 ± 5.04 1.94 ± 0.24
RT112rGEMCI20luc 27.36 ± 3.6 114.39 ± 14.52